CJC-1295 with DAC 5mg

CJC-1295 with DAC 5 mg is a high-purity lyophilized peptide research compound supplied exclusively for scientific investigation and controlled laboratory experimentation. For research use only — not for human or veterinary use.  

Product Overview

CJC-1295 with DAC is a synthetic peptide research compound developed for advanced laboratory investigations involving peptide receptor biology, growth hormone-releasing factor research and intracellular molecular signalling. The DAC modification distinguishes this compound within the broader field of growth hormone-releasing peptide research and makes it of particular interest for controlled investigations involving modified peptide structures and receptor-mediated signalling pathways. This preparation contains 5 mg of lyophilized CJC-1295 with DAC supplied in a sealed research vial. Independent analytical testing confirmed an assay content of 4.70 mg for this production batch. Chromatographic analysis confirmed 98.9 percent purity, while identity was independently evaluated through FTIR spectrum analysis, retention time confirmation and molecular ion mass identification. Microbiological testing reported 0 CFU/g for both total aerobic microbial count and total yeast and mold count, while bacterial endotoxin analysis returned a result of 0.020 EU/mg. Comprehensive elemental impurity screening additionally reported arsenic, cadmium, mercury, lead, nickel, vanadium and cobalt below 0.001 ppm. With its defined molecular identity, reproducible analytical profile and comprehensive third-party verification, CJC-1295 with DAC provides researchers with a well-characterised peptide material suitable for advanced peptide investigations and controlled in vitro laboratory studies.  

Peptide Overview

CJC-1295 with DAC is a synthetic peptide research compound commonly utilised in laboratory investigations involving peptide chemistry, receptor biology and molecular signalling systems. The compound belongs to the broader field of modified growth hormone-releasing factor peptide research and incorporates a Drug Affinity Complex (DAC) modification as part of its molecular design. Researchers employ CJC-1295 with DAC in controlled experimental models designed to investigate peptide-receptor interactions, growth hormone-related molecular signalling and complex biochemical regulatory pathways. Its defined molecular structure and reproducible analytical characteristics allow identity and quality parameters to be evaluated using complementary chromatographic, spectroscopic and mass spectrometric techniques. Today, CJC-1295 with DAC continues to form part of experimental peptide research involving receptor biology, peptide chemistry and molecular regulatory mechanisms.  

Historical Background and Scientific Context

Advances in peptide engineering have enabled researchers to develop modified peptide structures for investigating receptor signalling and molecular communication under controlled experimental conditions. Growth hormone-releasing factor analogues represent an established area of peptide research, with structural modifications providing additional opportunities for comparative investigations involving peptide stability, molecular interactions and receptor-associated signalling. The incorporation of DAC technology into peptide research compounds represents one approach to modifying the molecular characteristics of growth hormone-releasing factor analogues. Modern analytical technologies including ultra-high-performance liquid chromatography, FTIR identification and mass spectrometry have significantly improved the ability to verify peptide identity, purity and manufacturing consistency across laboratory-grade research compounds. Today, CJC-1295 with DAC remains part of the expanding field of investigational peptides utilised exclusively for scientific research and controlled in vitro experimentation.  

Mechanistic Focus in Research

Within controlled laboratory environments, CJC-1295 with DAC is commonly investigated in relation to peptide receptor signalling and growth hormone-releasing factor-associated molecular pathways. Research investigations frequently explore:

• Peptide receptor signalling pathways
• Growth hormone-releasing factor research
• Modified peptide structure investigations
• Receptor-mediated intracellular communication
• Cellular regulatory mechanisms
• Biochemical pathway analysis
• Comparative peptide investigations
• Controlled molecular interaction studies

These experimental models allow researchers to investigate complex peptide-mediated signalling mechanisms while maintaining carefully controlled laboratory conditions.  

Analytical Verification (COA)

Each batch of CJC-1295 with DAC supplied by Grail Formula undergoes comprehensive independent third-party laboratory verification to confirm peptide identity, assay content, purity and microbiological quality. Analytical testing for this batch was performed by Liquilabs s.r.o. Czechia using chromatographic, spectrometric, microbiological and mass spectrometry techniques. Batch: GF-CJCWD5-B241

• Assay Content: 4.70 mg
• Purity: 98.9 %
• Identification by FTIR Spectrum: 997
• Identification by Retention Time: 0.998
• Molecular Ion Mass Identification: 3647 Da
• Bacterial Endotoxins: 0.020 EU/mg
• Total Aerobic Microbial Count: 0 CFU/g
• Total Yeast and Mold Count: 0 CFU/g

Independent peptide screening measured an assay content of 4.70 mg with a reported analytical uncertainty of ±0.02 mg. Purity analysis confirmed 98.9 percent purity with a reported analytical uncertainty of ±0.5 percent. Identity was evaluated through FTIR spectrum analysis with a reported result of 997 and retention time analysis with a result of 0.998. Mass spectrometry identified a molecular ion mass of 3647 Da with a reported analytical uncertainty of ±1 Da, providing an additional independent identity parameter for the tested material. Bacterial endotoxin testing returned a result of 0.020 EU/mg, remaining within the laboratory’s stated acceptable range of 0–0.5 EU/mg. Microbiological testing reported 0 CFU/g for total aerobic microbial count and 0 CFU/g for total yeast and mold count. Independent elemental impurity analysis reported arsenic, cadmium, mercury, lead, nickel, vanadium and cobalt below 0.001 ppm. These analytical procedures provide independent confirmation of peptide identity, purity, traceability and important batch-specific laboratory quality parameters.  

Research Applications

Within controlled laboratory environments, CJC-1295 with DAC may be utilised in experimental models designed to investigate peptide receptor biology, intracellular signalling pathways and molecular regulatory mechanisms. Examples of research applications include:

• Growth hormone-releasing factor investigations
• Peptide receptor signalling research
• Modified peptide structure studies
• Intracellular signalling investigations
• Molecular pathway analysis
• Biochemical regulation studies
• Comparative peptide investigations
• Controlled in vitro peptide studies

These applications are intended exclusively for scientific and laboratory investigation.  

Grail Formula Quality

Every Grail Formula research compound is supported by comprehensive independent analytical verification and transparent batch-specific laboratory documentation. Each production batch undergoes extensive testing to verify:

• Peptide identity confirmation
• Assay content verification
• Purity assessment
• Molecular ion mass verification
• Retention time confirmation
• FTIR spectrum identification
• Endotoxin analysis
• Microbial contamination screening
• Elemental impurity screening
• Complete batch traceability

Independent laboratory testing helps provide researchers with reliable, reproducible and transparently documented research material suitable for advanced scientific investigation.  

When You Choose Grail Formula

When selecting Grail Formula, researchers receive independently verified research compounds supported by complete Certificates of Analysis and transparent batch-specific laboratory documentation. Our analytical verification programme includes assay determination, purity confirmation, FTIR spectrum identification, retention time verification, molecular ion mass identification, endotoxin screening, microbiological analysis and comprehensive elemental impurity testing. Every production batch is accompanied by a downloadable Certificate of Analysis issued by Liquilabs s.r.o. Czechia, providing complete traceability, independent verification and confidence in the analytical quality of every research compound supplied.  

Research Use Limitation

• Used solely for laboratory and in vitro research
• Not approved for human consumption
• Not approved for veterinary use
• Not intended for diagnostic purposes
• Not intended for therapeutic applications
• Not permitted for clinical administration
• For research use only

• Independently analysed by Liquilabs s.r.o. Czechia
• 98.9 % purity confirmed by COA
• Assay content verified at 4.70 mg
• Identification confirmed by FTIR spectrum and retention time analysis
• Molecular ion mass identified at 3647 Da
• Bacterial endotoxin level of 0.020 EU/mg
• No detectable heavy metals or microbial contamination
• Research-grade peptide compound
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.